MRI-Based Deep Learning Method for Classification of IDH Mutation Status
暂无分享,去创建一个
A. Madhuranthakam | B. Wagner | K. Hatanpaa | J. Holcomb | C. G. Bangalore Yogananda | Rajan Jain | Matthew D. Lee | Nghi C. D. Truong | Divya D. Reddy | Niloufar Saadat | Toral R. Patel | Baowei Fei | Richard J. Bruce | Marco C. Pinho | J. A. Maldjian | Nghi C D Truong | Divya Reddy | B. Fei | Richard J Bruce | M. C. Pinho
[1] C. Del Gratta,et al. Combining Multi-Shell Diffusion with Conventional MRI Improves Molecular Diagnosis of Diffuse Gliomas with Deep Learning , 2023, Cancers.
[2] J. Mongan,et al. The University of California San Francisco Preoperative Diffuse Glioma MRI Dataset. , 2021, Radiology. Artificial intelligence.
[3] Christos Davatzikos,et al. The RSNA-ASNR-MICCAI BraTS 2021 Benchmark on Brain Tumor Segmentation and Radiogenomic Classification , 2021, ArXiv.
[4] S. Klein,et al. The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with glioma , 2021, Data in brief.
[5] A. Stoppacciaro,et al. Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM , 2021, Journal of personalized medicine.
[6] Jens Petersen,et al. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation , 2020, Nature Methods.
[7] Spyridon Bakas,et al. Federated learning in medicine: facilitating multi-institutional collaborations without sharing patient data , 2020, Scientific Reports.
[8] Seok-Gu Kang,et al. Fully Automated Hybrid Approach to Predict the IDH Mutation Status of Gliomas via Deep Learning and Radiomics. , 2020, Neuro-oncology.
[9] K. Masamune,et al. Prediction of lower-grade glioma molecular subtypes using deep learning , 2019, Journal of Neuro-Oncology.
[10] Natalia Gimelshein,et al. PyTorch: An Imperative Style, High-Performance Deep Learning Library , 2019, NeurIPS.
[11] Sahil Nalawade,et al. Classification of brain tumor isocitrate dehydrogenase status using MRI and deep learning , 2019, Journal of medical imaging.
[12] Sang Joon Kim,et al. False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis. , 2019, Radiology.
[13] Ronald M. Summers,et al. A large annotated medical image dataset for the development and evaluation of segmentation algorithms , 2019, ArXiv.
[14] Wenya Linda Bi,et al. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas , 2019, Journal of Neuro-Oncology.
[15] et al.,et al. Identifying the Best Machine Learning Algorithms for Brain Tumor Segmentation, Progression Assessment, and Overall Survival Prediction in the BRATS Challenge , 2018, ArXiv.
[16] Jie Yang,et al. Deep Learning on MRI Affirms the Prominence of the Hippocampal Formation in Alzheimer’s Disease Classification , 2018, bioRxiv.
[17] Baojuan Li,et al. Radiomics Strategy for Molecular Subtype Stratification of Lower‐Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI , 2018, Journal of magnetic resonance imaging : JMRI.
[18] P. Baldi,et al. Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas , 2018, American Journal of Neuroradiology.
[19] Joachim M. Buhmann,et al. Classification of brain MRI with big data and deep 3D convolutional neural networks , 2018, Medical Imaging.
[20] Karra A. Jones,et al. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status , 2017, Journal of Neuro-Oncology.
[21] Sébastien Ourselin,et al. Automatic Brain Tumor Segmentation Using Cascaded Anisotropic Convolutional Neural Networks , 2017, BrainLes@MICCAI.
[22] Wei Cao,et al. Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma , 2017, Scientific Reports.
[23] E. Maher,et al. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. , 2017, Journal of neurosurgery.
[24] Gregory A. Breuer,et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity , 2017, Science Translational Medicine.
[25] Yoshua Bengio,et al. The One Hundred Layers Tiramisu: Fully Convolutional DenseNets for Semantic Segmentation , 2016, 2017 IEEE Conference on Computer Vision and Pattern Recognition Workshops (CVPRW).
[26] J. Buckner,et al. MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas , 2016, Medical physics.
[27] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[28] Pieter Wesseling,et al. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. , 2016, Neuro-oncology.
[29] L. Deangelis,et al. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. , 2016, Neuro-oncology.
[30] Steven J. M. Jones,et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.
[31] D. Louis,et al. The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas , 2016, Journal of neuropathology and experimental neurology.
[32] W. Vandertop,et al. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. , 2015, Cancer research.
[33] Keith L. Ligon,et al. Somatic mutations associated with MRI-derived volumetric features in glioblastoma , 2015, Neuroradiology.
[34] Yehani Wedatilake,et al. Tubular aggregates caused by serine active site containing 1 (SERAC1) mutations in a patient with a mitochondrial encephalopathy , 2015, Neuropathology and applied neurobiology.
[35] N. Risch,et al. Estimating genotype error rates from high-coverage next-generation sequence data , 2014, Genome research.
[36] Arno Klein,et al. Large-scale evaluation of ANTs and FreeSurfer cortical thickness measurements , 2014, NeuroImage.
[37] R. Beroukhim,et al. Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas , 2014, Oncotarget.
[38] Stephen M. Moore,et al. The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository , 2013, Journal of Digital Imaging.
[39] A. von Deimling,et al. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death , 2013, Apoptosis.
[40] Pankaj Pathak,et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. , 2013, Neuro-oncology.
[41] Y. Suh,et al. IDH1 Mutations in Oligodendroglial Tumors: Comparative Analysis of Direct Sequencing, Pyrosequencing, Immunohistochemistry, Nested PCR and PNA‐Mediated Clamping PCR , 2013, Brain pathology.
[42] C. Horbinski. What do we know about IDH1/2 mutations so far, and how do we use it? , 2013, Acta Neuropathologica.
[43] Minako Sumi,et al. IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. , 2012, International journal of oncology.
[44] T. Cloughesy,et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy , 2012, Journal of Neuro-Oncology.
[45] Yan Ding,et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma , 2012, Cancer science.
[46] M A Griswold,et al. Comparison of Brain MR Images at 1.5T Using BLADE and Rectilinear Techniques for Patients Who Move during Data Acquisition , 2012, American Journal of Neuroradiology.
[47] Dinesh Rakheja,et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients , 2011, Nature Medicine.
[48] J. Hainfellner,et al. Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the IDH1-R132H Mutation in Diffuse Glioma Biopsy Specimens , 2011, Journal of neuropathology and experimental neurology.
[49] Arno Klein,et al. A reproducible evaluation of ANTs similarity metric performance in brain image registration , 2011, NeuroImage.
[50] Brian B. Avants,et al. N4ITK: Improved N3 Bias Correction , 2010, IEEE Transactions on Medical Imaging.
[51] Adolf Pfefferbaum,et al. The SRI24 multichannel atlas of normal adult human brain structure , 2009, Human brain mapping.
[52] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[53] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[54] A. Sowmya,et al. Automated Brain Tumor Segmentation Using Multimodal Brain Scans: A Survey Based on Models Submitted to the BraTS 2012–2018 Challenges , 2020, IEEE Reviews in Biomedical Engineering.
[55] Raymond Y Huang,et al. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas , 2017, Neuro-oncology.
[56] K. Aldape,et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. , 2014, Neuro-oncology.